Status:

COMPLETED

Clinical Application of PD-1 Inhibitor in Colorectal Cancer for Improving Survival

Lead Sponsor:

Yanhong Deng

Conditions:

Rectal Cancer

Colon Cancer

Eligibility:

All Genders

Brief Summary

This trial is a single-center retrospective study. Eligible patients receiving PD-1 inhibitor treatment will enrolled.

Detailed Description

In patients with colorectal cancer (CRC), curative surgery combined with chemotherapy ( FOLFOX or CAPOX regimens) has become the standard treatment. However, 20 to 30% of these patients will develop d...

Eligibility Criteria

Inclusion

  • :
  • Willing and able to provide written informed consent. Histological or cytological documentation of adenocarcinoma of the colorectal. Eastern Cooperative Oncology Group's (ECOG) performance status of 0 or 1. CT or MRI scans (done within 30 days of registration) of the chest, abdomen, and pelvis all without clear evidence of distant metastatic (M1) disease.
  • No clinically significant obstruction, perforation, or bleeding related to the primary tumor.
  • No previous systemic anticancer therapy for colon cancer disease. Adequate bone marrow, hepatic, and renal function as assessed by the following laboratory requirements conducted within 7 days of starting the study treatment

Exclusion

  • Previous or concurrent cancer that is distinct in primary site or histology from colon cancer within 5 years before randomization.
  • Significant cardiovascular disease including unstable angina or myocardial infarction within 6 months before initiating study treatment.
  • Heart failure grade III/IV (NYHA classification). Unresolved toxicity higher than CTCAE v.5.0 Grade 1 attributed to any prior therapy/procedure.
  • Subjects with known allergy to the study drugs or any of its excipients. Current or recent (within 4 weeks before starting study treatment) treatment of another investigational drug or participation in another investigational study.
  • Breast-feeding or pregnant women Lack of effective contraception.

Key Trial Info

Start Date :

March 20 2013

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

March 23 2025

Estimated Enrollment :

458 Patients enrolled

Trial Details

Trial ID

NCT06900686

Start Date

March 20 2013

End Date

March 23 2025

Last Update

March 28 2025

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.